SynBioBeta Speaker
Ola Wlodek
Constructive Bio
CEO
Ola is the CEO of Constructive Bio, a spinout from Jason Chin's lab in Cambridge, UK. The company is dedicated to broadening the range of building blocks for peptides and proteins produced recombinantly, leveraging cutting-edge synthetic genomics and engineered translation to unlock new possibilities for biopharma and beyond. Ola holds a PhD in Biological Sciences from the University of Cambridge and an Executive MBA from Warwick Business School, combining deep scientific expertise with strategic leadership skills. Her scientific career has been driven by a fascination with designing and producing 'unnatural'products through biological means-”transforming synthetic biology from exploration to purposeful innovation.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ola
This Year
•
-
Tools & Tech
Engineering Resilient Pharma Supply Chains with Biology
For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.
Get a Ticket
Featuring
Ola Wlodek
Constructive Bio
CEO
Leader in Non-Canonical Amino Acids and genome design
Christina Smolke
Antheia
CEO & Co-Founder
Synthetic-biology pioneer decoupling medicines from fragile supply chains.
Tina Boville
Aralez Bio
Co-founder & CEO
Enzyme engineer expanding peptide chemistry’s noncanonical frontier.
•
-
Tools & Tech
Engineering Resilient Pharma Supply Chains with Biology
For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.
Get a Ticket
Featuring
Ola Wlodek
Constructive Bio
CEO
Leader in Non-Canonical Amino Acids and genome design
Christina Smolke
Antheia
CEO & Co-Founder
Synthetic-biology pioneer decoupling medicines from fragile supply chains.
Tina Boville
Aralez Bio
Co-founder & CEO
Enzyme engineer expanding peptide chemistry’s noncanonical frontier.
•
-
Tools & Tech
Beyond Nature’s Alphabet: The Rise of Programmable Biomolecules
Biology has long relied on a limited molecular vocabulary shaped by natural evolution. Today, that alphabet is expanding. Advances in expanded genetic codes, non-canonical amino acids, macrocycles, de novo design, and AI-guided protein engineering are enabling scientists to create biomolecules with properties and functions that nature never evolved. This session explores the rise of programmable biomolecules at the intersection of biology, chemistry, and computation. Rather than simply optimizing existing proteins, researchers are building entirely new classes of functional molecules with novel architectures, chemistries, and therapeutic potential. From next-generation biologics to hybrid molecular scaffolds, the discussion will examine how the field is moving beyond nature’s defaults and toward a future where biomolecules can be designed with increasing precision, flexibility, and intent.
Get a Ticket
•
-
Tools & Tech
Beyond Nature’s Alphabet: The Rise of Programmable Biomolecules
Biology has long relied on a limited molecular vocabulary shaped by natural evolution. Today, that alphabet is expanding. Advances in expanded genetic codes, non-canonical amino acids, macrocycles, de novo design, and AI-guided protein engineering are enabling scientists to create biomolecules with properties and functions that nature never evolved. This session explores the rise of programmable biomolecules at the intersection of biology, chemistry, and computation. Rather than simply optimizing existing proteins, researchers are building entirely new classes of functional molecules with novel architectures, chemistries, and therapeutic potential. From next-generation biologics to hybrid molecular scaffolds, the discussion will examine how the field is moving beyond nature’s defaults and toward a future where biomolecules can be designed with increasing precision, flexibility, and intent.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
